Literature DB >> 6218120

[In vitro effect of acylureido penicillins and mezlocillin on anaerobic sporeless gram-negative rods of genus Bacteroides].

C Höhne.   

Abstract

313 anaerobic gram-negative rods of the Bacteroides genus isolated from 295 clinical specimens were tested for their sensitivity to azlocillin and mezlocillin using the dilution method with agar plates. 25 mg/l of azlocillin inhibited 80.2% of the strains and the same concentration of mezlocillin inhibited 86.9%. The somewhat higher in vitro activity of mezlocillin is also seen by the lower mean minimal inhibitory concentration, which is approx. 23.6 mg/l for mezlocillin and 27.6 mg/l for azlocillin. The highest resistance for both drugs were found with B. distasonis (14 strains), followed by B. thetaiotaomicron (63 strains), B. fragilis (161 strains) and B. uniformis (7 strains). The good sensitivity of strains belonging to the B. melaninogenicus group corresponds to the well-known sensitivity of these micro-organisms to penicillins. On the basis of a "break point" of 25 mg/l, a decrease in the proportion of sensitive strains was found between 1974 and 1979. 50 mg/l, a concentration which can be maintained over a longer period of time if applied in a suitable manner, will inhibit 97.4% (azlocillin) and 98.4% (mezlocillin) of the strains. Thus in our opinion azlocillin and especially mezlocillin are suitable drugs for the initial therapy of pyogenous infections in which intestinal Bacteroidaceae are of pathogenic significance.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6218120     DOI: 10.1007/bf01640681

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  [A new butyric acid-producing bacteroides species: B. splanchnicus n. sp. (author's transl)].

Authors:  H Werner; G Rintelen; H Kunstek-Santos
Journal:  Zentralbl Bakteriol Orig A       Date:  1975

2.  Azlocillin and mezlocillin, two new alpha-amino-substituted penicillins. A comparison of the in vitro activity with other penicillins.

Authors:  R Wise
Journal:  Arzneimittelforschung       Date:  1979

3.  Differentiation and medical importance of saccharolytic intestinal Bacteroides.

Authors:  H Werner
Journal:  Arzneimittelforschung       Date:  1974-03

4.  [A replicator for resistance determinations].

Authors:  C Höhne
Journal:  Z Med Lab Diagn       Date:  1979-08

5.  [In vitro activity of mezlocillin, azlocillin and carbenicillin against bacteroidaceae with particular reference to bacteroides fragilis (author's transl)].

Authors:  H Werner; C Krassemann; J Ungerechts; H J Schmitz
Journal:  Infection       Date:  1977       Impact factor: 3.553

6.  Susceptibility of anaerobic bacteria to 23 antimicrobial agents.

Authors:  V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

7.  [Propionate negative saccharolytic bacteroides strains (B. oralis)-occurrence, identification, antimicrobial susceptibility and serological behaviour (author's transl)].

Authors:  H Werner; H Kunstek-Santos; C Lohner; W Schöps; H J Schmitz; H H Karbe
Journal:  Zentralbl Bakteriol Orig A       Date:  1977-04

8.  Azlocillin and mezlocillin: new ureido penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

9.  [Azlocillin and mezlocillin: two new semisynthetic acylureido-penicillins (author's transl)].

Authors:  H Lode; U Niestrath; P Koeppe; H Langmaack
Journal:  Infection       Date:  1977       Impact factor: 3.553

10.  In vitro activity of mezlocillin and its related compounds against aerobic and anaerobic bacteria.

Authors:  H Thadepalli; I Roy; V T Bach; D Webb
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

View more
  1 in total

1.  Identification and susceptibility patterns of anaerobic bacteria isolated from clinical specimens during a one-year period.

Authors:  A C Rodloff; G Görtz; H Ponnath; H Hahn
Journal:  Infection       Date:  1984 Nov-Dec       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.